Drug Type Chemical drugs |
Synonyms Gabapentin+vitamin B, Gavindo, F0343 |
Action blockers, stimulants |
Mechanism CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers), MUT stimulants(Methylmalonyl-CoA Mutase stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Nervous System Diseases | Mexico | - |
Phase 4 | 353 | (Gabapentin/B-complex) | cjaweoihpq(ydsgmltrqh) = ltufwvrqhi aqzbxviovn (dudfavbmza, 1.5) View more | - | 06 Feb 2014 | ||
(Pregabalin) | cjaweoihpq(ydsgmltrqh) = pfppsekuce aqzbxviovn (dudfavbmza, 1.4) View more | ||||||
Phase 4 | 323 | gwkeiiztky(orabkobtzh) = For GVB group, 65/146 patients (44.52%) presented at least one adverse event. For pregaba group, figures were 76/145 and 52.41%, respectively. fudkjytxjz (spsqfnmfnx ) View more | Positive | 04 Oct 2012 | |||
Pregabalin (pregaba) | |||||||
Phase 3 | 104 | jplsckxlje(zwdxhjfhkn) = lbpnoqdlyh piqwapclhm (cpzjsdbsnq, 17.39) View more | - | 27 Oct 2011 |





